ArticleOncoTargets and therapy2020

MiR-140 Resensitizes Cisplatin-Resistant NSCLC Cells to Cisplatin Treatment Through the SIRT1/ROS/JNK Pathway.

Zhilai Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.